熱門資訊> 正文
Enanta在RSV抗病毒药物中期试验数据公布之前成为焦点
2025-09-27 21:08
- Enanta Pharmaceuticals (NASDAQ:ENTA) has set up a conference call for Monday at 8:30 a.m. ET to disclose mid-stage trial data for its antiviral candidate zelicapavir, targeted at infections caused by the respiratory syncytial virus.
- Shares of Enanta (NASDAQ:ENTA) gained ~17% in the after-hours trading on Friday after the Watertown, Massachusetts-based biotech announced the upcoming topline readout from its RSVHR study designed to test zelicapavir for RSV in high-risk adults.
- The Phase 2b study has enrolled adults with RSV who are at high risk of complications linked to the respiratory infection, including people over the age of 65 and/or those with non-communicable diseases such as asthma and congestive heart failure.
- Last month, the company reiterated its plans to post initial data from the placebo-controlled trial in September, noting that enrollment was complete with the addition of 186 adults.
More on Enanta Pharma
- Pfizer sued by Enanta in EU over patent infringement related to COVID pill
- Enanta Pharma GAAP EPS of -$0.85 beats by $0.04, revenue of $18.31M beats by $2.68M
- Seeking Alpha’s Quant Rating on Enanta Pharma
- Historical earnings data for Enanta Pharma
- Financial information for Enanta Pharma
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
